Home/Filings/4/0000899243-21-010018
4//SEC Filing

Snyder Douglas B. 4

Accession 0000899243-21-010018

CIK 0001351288other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 9:01 PM ET

Size

8.9 KB

Accession

0000899243-21-010018

Insider Transaction Report

Form 4
Period: 2021-03-02
Snyder Douglas B.
Chief Legal Officer
Transactions
  • Award

    Share Options

    2021-03-02+72,25872,258 total
    Exercise: $0.00Ordinary Shares (72,258 underlying)
  • Award

    Share Options

    2021-03-02+45,36045,360 total
    Exercise: $0.00Ordinary Shares (45,360 underlying)
Footnotes (6)
  • [F1]Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied.
  • [F2]Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021.
  • [F3]Granted pursuant to the Issuer's Long-Term Incentive Plan.
  • [F4]These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting.
  • [F5]Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc.
  • [F6]The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4.

Issuer

GW PHARMACEUTICALS PLC

CIK 0001351288

Entity typeother

Related Parties

1
  • filerCIK 0001754125

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 9:01 PM ET
Size
8.9 KB